 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
15 June 1994 | Volume 120 Issue 12 | Pages 1047-1048
I would like to clarify an issue raised in the excellent review of glucocorticoid resistance by Chrousos and colleagues [1] regarding a putative variant form of glucocorticoid receptor. Such a variant could indeed be analogous to the
1. Chrousos GP, Detera-Wadleigh SD, Karl M. Syndromes of glucocorticoid resistance. Ann Intern Med. 1993; 119:1113-24.
2. Koenig RJ, Lazar MA, Hodin RA, Brent GA, Larsen PR, Chin WW, et al. Inhibition of thyroid hormone action by a non-hormone binding c-erbA protein generated by alternative mRNA splicing. Nature. 1989; 337:659-61.
3. Lazar MA, Hodin RA, Chin WW. Human carboxyl-terminal variant of 4. Katz D, Berrodin TJ, Lazar MA. The unique C-termini of the thyroid hormone receptor variant, c-erbA 5. Katz D, Lazar MA. Dominant negative activity of an endogenous thyroid hormone receptor variant ( About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
LETTER
Glucocorticoid Resistance
TO THE EDITOR: 
2 form of the thyroid hormone receptor, which does not bind thyroid hormone but can inhibit thyroid hormone action [2, 3]. Formation of inactive heterodimers with thyroid hormone receptors has been postulated; however, we have more recently found that the 2 thyroid hormone receptor does not form stable heterodimers with other thyroid hormone receptors [4]. Rather, its dominant inhibition of thyroid hormone action is caused by direct competition with the other receptors for thyroid hormone response elements in target genes [5].
Author and Article Information
Top
Author & Article Info
References
University of Pennsylvania School of Medicine; Philadelphia, PA 19104
References
Top
Author & Article Info
References
-type c-erbA inhibits trans-activation by thyroid hormone receptors without binding thyroid hormone. Proc Natl Acad Sci U S A. 1989; 86:7771-4.
2, and the thyroid hormone receptor 1 mediate different DNA-binding and heterodimerization properties. Mol Endocrinol. 1992; 6:805-14.
2) is due to competition for binding sites on target genes. J Biol Chem. 1993; 268:20904-10.
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
| |||||||||||||||||||||||||||||||||||||||||||||||||
Article
